Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression

Andrillon, A., Chevret, S., Lee, S. M., & Biard, L. (2022). Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression. Statistics in Medicine, 41(29), 5753–5766. Portico. https://doi.org/10.1002/sim.9591

Authors:

Anaïs Andrillon

Sylvie Chevret

Shing M Lee

Lucie Biard

Affiliated Authors:

Anaïs Andrillon

Shing M Lee

Columbia Affiliation: